• Home Today announced the presentation of interim outcomes from the first Stage I/II trial of samalizumab ed piller.

Today announced the presentation of interim outcomes from the first Stage I/II trial of samalizumab ed piller.

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody Alexion Pharmaceuticals, Inc. today announced the presentation of interim outcomes from the first Stage I/II trial of samalizumab, the company’s investigational, first-in-class humanized monoclonal antibody ed piller . The ongoing trial is evaluating the security, maximum tolerated dosage, pharmacokinetics, and pharmacodynamics of samalizumab in adult individuals with advanced stage B-cell chronic lymphocytic leukemia or multiple myeloma . Data offered today at the 52nd American Society of Hematology Annual Interacting with and Exposition in Orlando indicate that samalizumab was well tolerated at all dosages studied, exhibited a dose-dependent pharmacokinetic and biological response, and exhibited initial evidence of anti-tumor activity.

ALFAUR was a double-blind, placebo-controlled trial including 363 patients with an initial episode of AUR related to benign prostatic hyperplasia . The ALFAUR trial was executed in two phases. In the first stage of the study patients were randomised to receive alfuzosin 10 mg OD or placebo for an interval of 2 to 3 3 days right from the start of catheterization to a trial without catheter . In this stage of the trial, alfuzosin 10 mg OD got an increased rate of successful voiding of the bladder after catheter removal weighed against placebo . Alfuzosin 10 mg OD nearly doubled the probability of a successful TWOC in these patients and its beneficial effect was especially marked in individuals with a high threat of TWOC failing, i.e.